Neuralink's Brain Implants and FDA Approval
Neuralink faces challenges as tiny wires in brain implants retract, potentially affecting brain signals; FDA aware of issue since animal testing; company aims to restore implant's function by making changes to algorithm; company seeks to design threads for seamless removal; company faces safety concerns and complications during trials; researchers debate causes of inflammation in brain; FDA issues notice for Trilogy EVO Continuous Ventilators
Key Points
- FDA aware of wire retraction issue since animal testing
- Neuralink aims to design threads for seamless removal and future updates to the implant
- Safety concerns and complications faced during trials
- Researchers debate causes of inflammation in the brain
- FDA issues notice for Trilogy EVO Continuous Ventilators
Pros
- Neuralink's brain implants could help paralyzed patients use digital devices through thought alone
- The company managed to restore the implant's ability to monitor brain signals by making changes to the algorithm
Cons
- Tiny wires in the brain implants retracted from a patient's brain during the first human trial
- Challenges may arise if more wires retract and the algorithm tweak is insufficient